| pubmed-article:11005049 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11005049 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:11005049 | lifeskim:mentions | umls-concept:C0013806 | lld:lifeskim |
| pubmed-article:11005049 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11005049 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:11005049 | lifeskim:mentions | umls-concept:C0599861 | lld:lifeskim |
| pubmed-article:11005049 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11005049 | pubmed:dateCreated | 2001-2-2 | lld:pubmed |
| pubmed-article:11005049 | pubmed:abstractText | Six factorially designed studies evaluated the effects of different schedules of electroconvulsive shocks (ECSs) on alpha-2 adrenoceptor function in the rat brain. Attenuation of the hypomotility response to a clonidine challenge was taken to indicate alpha-2 adrenoceptor downregulation, a putative mediator of antidepressant action. Six daily and six alternate-day ECSs were shown separately to produce this receptor change. Three alternate-day ECSs produced comparable downregulation for a comparable period as six daily ECSs; this suggests that ECS produces time-dependent effects. No changes were elicited with a single ECS, which indicates that a single ECS may not influence alpha-2 receptor function. Three daily ECSs produced brief downregulation, which has implications for receptor dynamics as a function of the ECS schedule. Finally, maintenance ECSs sustained alpha-2 adrenoceptor downregulation over 6 weeks, which suggests a possible neurochemical basis for maintenance electroconvulsive therapy. The clinical relevance and scope for further research are discussed. | lld:pubmed |
| pubmed-article:11005049 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11005049 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11005049 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11005049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11005049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11005049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11005049 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11005049 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:11005049 | pubmed:issn | 1095-0680 | lld:pubmed |
| pubmed-article:11005049 | pubmed:author | pubmed-author:AndradeCC | lld:pubmed |
| pubmed-article:11005049 | pubmed:author | pubmed-author:SudhaSS | lld:pubmed |
| pubmed-article:11005049 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11005049 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:11005049 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11005049 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11005049 | pubmed:pagination | 268-78 | lld:pubmed |
| pubmed-article:11005049 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:meshHeading | pubmed-meshheading:11005049... | lld:pubmed |
| pubmed-article:11005049 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11005049 | pubmed:articleTitle | Electroconvulsive therapy and the alpha-2 noradrenergic receptor: implications of treatment schedule effects. | lld:pubmed |
| pubmed-article:11005049 | pubmed:affiliation | Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India. candrade@bgl.vsnl.net.in | lld:pubmed |
| pubmed-article:11005049 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11005049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11005049 | lld:pubmed |
